Begin main content

Canadian Drug Expert Committee (CDEC)

The Canadian Drug Expert Committee (CDEC) is an appointed, pan-Canadian advisory body to CADTH composed of individuals with expertise in drug therapy, drug evaluation and drug utilization, and public members (for a lay perspective).

As part of the CADTH Common Drug Review (CDR) process, CDEC makes recommendations to each of the participating federal, provincial, and territorial publicly funded drug plans regarding the listings on their formularies. It also makes recommendations related to the identification, evaluation, and promotion of optimal drug prescribing and use in Canada.

CDEC's approach is evidence based, and the advice reflects medical and scientific knowledge, current clinical practice, economics, ethical considerations, and patient and public impact.

CDEC is appointed by, and reports to, CADTH's President and CEO. Members must abide by the Conflict of Interest Guidelines for CADTH Expert Committee and Panel Members and the CADTH Code of Conduct. An honorarium is paid to CDEC members for their preparation and meeting time.

CDEC Terms of Reference
CDEC Meeting Schedule

Chair

Dr. Jim Silvius, BA (Oxon), MD, FRCPC
Dr. Silvius is an Associate Professor in the Cumming School of Medicine, Division of Geriatric Medicine, at the University of Calgary. At Alberta Health Services (AHS), he is the Provincial Medical Director of Seniors Health and the Senior Medical Director, Seniors Health Strategic Clinical Network. He was the previous Medical Director of AHS Pharmacy Services, a member of the Alberta Health and Wellness Expert Committee on Drug Evaluation and Therapeutics between 1999 and 2003, and chair of that committee from 2004 to 2015. He is also a former member of CADTH’s Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) Expert Review Committee. Dr. Silvius maintains a clinical practice in geriatrics at Rockyview General Hospital. His other interests include dementia care, care delivery, and deprescribing at the Canadian Deprescribing Network (CaDeN) where he is a Co-Director.
Conflict of Interest Disclosure

 

Members

Dr. Silvia Alessi-Severini, PhD 
Dr. Alessi-Severini received her pharmacy degree from the University of Parma (Italy) and her PhD in pharmaceutical sciences from the University of Alberta. She is currently an Associate Professor at the University of Manitoba in the Faculty of Health Sciences (College of Pharmacy), where she teaches in the areas of toxicology, pharmaceutical policy, and pharmacoepidemiology. Her research program includes studies of utilization, safety, and effectiveness of psychotropic medications. Silvia is also an Adjunct Scientist with the Manitoba Centre for Health Policy and a member of the Manitoba team of the Canadian Network for Observational Drug Effect Studies. Since 2008, she has been involved with the Association of Faculties of Pharmacy of Canada (AFPC), including serving as Chair of Council and Chair of the Research Committee. She is currently a member of the AFPC Board of Directors. Over the years, Silvia has been extensively involved with the provincial drug programs in Alberta and Manitoba, and she has been serving on the Manitoba Drug Standards and Therapeutics Committee since 2004.
Conflict of Interest Disclosure

Dr. Ahmed Bayoumi, MSc, MD
Dr. Bayoumi is a scientist at the Centre for Research on Inner City Health at the Keenan Research Centre in the Li Ka Shing Knowledge Institute, St. Michael's Hospital. He is also a general internist and HIV physician at St. Michael's Hospital, and past Director of Clinical Epidemiology and Health Care Research at the University of Toronto's Institute of Health Policy, Management and Evaluation. His research interests include equity and resource allocation, economic evaluation, quality of life assessment for HIV-related health interventions, and access to health services delivery for marginalized populations, including people living with HIV and people who use drugs. Ahmed is an adjunct scientist at the Institute for Clinical Evaluative Sciences. He is President of the Society for Medical Decision Making for 2014 to 2015.
Conflict of Interest Disclosure

Dr. Bruce C. Carleton, PharmD
Dr. Carleton earned a bachelor's degree in pharmaceutical sciences from Washington State University and a Doctor of Pharmacy from the University of Utah. He joined the University of British Columbia in 1991, and is currently Professor of Pediatrics and Pharmaceutical Sciences and Co-Chair, Division of Translational Therapeutics, in the Faculty of Medicine. Bruce also serves as Director, Pharmaceutical Outcomes Programme, BC Children's Hospital, and is Senior Clinician Scientist at the Child & Family Research Institute in Vancouver, British Columbia. His research focuses on the impact of drug therapy on human health and quality of life. He is particularly interested in developing better ways to evaluate the effectiveness of drugs, medication-use models designed to improve patient health, and practical surveillance systems to improve the safe use of medication. Bruce has particular clinical interests in asthma and the clinical use of drugs in children; and in the epidemiology, pharmacogenomics, and clinical management of adverse drug events.
Conflict of Interest Disclosure

Dr. Alun Edwards
Alun Edwards is Professor of Medicine at the Cumming School of Medicine, University of Calgary, and a clinical endocrinologist. He has a longstanding interest in the pragmatic translation of evidence into practice, and in considering resource distribution in health system development and outcomes measurement.

His most recent work in this area was as the inaugural Senior Medical Director for the Alberta Health Services Diabetes, Obesity and Nutrition Strategic Clinical Network. He also chaired the Quality Improvement Committee of the Canadian Society of Endocrinology and Metabolism, which developed recommendations for the specialty.

Mr. Bob Gagne
Bob Gagne holds an MBA from York University and a BSc from Western University. He has held a number of senior leadership roles over the past 30 years including four years in planning and strategy development with a global financial institution, eight years as director of information technology in a teaching hospital in Toronto, and three years as director of strategic technology for a top Canadian Internet portal. Most recently he was the chief information officer at York University for eighteen years before retiring in 2017. Bob has served on multiple industry and community boards of directors including the boards of Onet, GTAnet networking, the Canadian University Council of CIOs, and the Canadian Association for Tay-Sachs and Allied Diseases. He is currently a member of the board of CANARIE. His experience with, and appreciation for, Canada’s health care system was strongly shaped by the life and care of his daughter Elizabeth who was born with Tay-Sachs disease, a rare, neurodegenerative genetic disorder.

Dr. Ran Goldman
Dr. Ran Goldman is a professor of pediatrics, a clinician-investigator and pediatrician, with a fellowship in pediatric emergency medicine and clinical pharmacology and toxicology. He did his specialized training in Toronto, and served as a Staff Physician at the Hospital for Sick Children (SickKids). He was then recruited to BC Children’s Hospital as the Chief of Emergency Medicine. Dr. Goldman also served as the Assistant Dean of Continuing Education at the University of British Columbia. He is currently the University’s Co-Chair of the Division of Pediatric Translational Therapeutics in the Faculty of Medicine, and a member of the BC Children’s Hospital Research Institute.

Dr. Goldman completed a Master of Health Research Methodology and trains numerous students in conducting effective research. His research program focuses on pain in the acute care setting and his lab findings resulted in an improved pain management approach for children worldwide. With more than 150 peer-reviewed publications, Dr. Goldman does not only discover, but successfully disseminates, his team’s findings into clinical practice guidelines for children with pain in the acute care setting. He is leading the world’s largest online resource for acute care medication research — Pediatric Research in Emergency Therapeutics (PRETx.ORG).

Dr. Allan Grill, MD, CCFP(COE), MPH, FCFP, CCPE
Dr. Allan Grill is an Assistant Professor in the Department of Family and Community Medicine at the University of Toronto and is the Lead Physician at the Markham Family Health Team. He enjoys an active community-based clinical practice and has a staff appointment at Markham Stouffville Hospital. As the current Chair of the Committee to Evaluate Drugs (CED), an expert advisory committee to the Ontario Ministry of Health and Long-Term Care on drug policy issues, as well as a former member of CADTH’s pan-Canadian Oncology Drug Review Expert Review Committee (pERC), Dr. Grill has experience in the critical appraisal of drug therapies as well as evaluating funding decisions for public formularies. Dr. Grill also serves in several primary care leadership roles. As the Primary Care Lead for the Ontario Renal Network, he is part of a team that focuses on innovative ways to improve the management of chronic kidney disease in the primary care setting. Dr. Grill earned a Bachelor of Science from McGill University, and completed his medical school and Family Medicine training at the University of Toronto. In 2004, Dr. Grill was awarded a Frank Knox Memorial Fellowship for graduate studies at Harvard University, obtaining his Master of Public Health degree.

Dr. Peter Jamieson, MD, CCFP, FCFP
Dr. Jamieson is a family physician practising in Calgary, Alberta and serves as Associate Zone Medical Director in Calgary and as Medical Director of the Foothills Medical Centre — a 1,062-bed quaternary academic medical centre. He is a Clinical Associate Professor in the Department of Family Medicine at the University of Calgary, with extensive experience in teaching at the undergraduate, graduate, and postgraduate levels. Peter has held leadership positions with the Alberta Medical Association, the American and Canadian societies of hospital medicine, and has been broadly consulted on the establishment, monitoring, outcomes, and improvement of in-patient care programs. He has a strong interest in health informatics, and is a consultant to Alberta Health Services and multiple other health delivery systems regarding implementation of clinical information systems, with a particular responsibility for systems design, clinical decision support, and content management.
Conflict of Interest Disclosure

Dr. Anatoly Langer, MD, MSc, FRCPC, FACC
Dr. Anatoly Langer graduated from the University of Manitoba in 1982 and completed his Internal Medicine and Cardiology training at the University of Toronto in 1987. He is a Fellow of the American College of Cardiology and of the Royal College of Physicians and Surgeons of Canada. After two years as a Heart and Stroke Foundation Research Fellow, he became Director of the Coronary Care Unit at St. Michael's Hospital in Toronto. In 1996, Anatoly founded the Canadian Heart Research Centre, with the goal of improving the care of cardiovascular patients through clinical trials research, physician and patient education, and information sharing.

Anatoly has extensive research experience in the conduct of clinical trials, with more than 25 years of experience in protocol design, study coordination, and data management. He has more than 250 peer-reviewed publications, abstracts, and book chapters. His areas of interest and research include pathophysiology and the management of acute and stable coronary syndromes, as well as the treatment and prevention of cardiovascular disease. Currently, Anatoly is a Professor of Medicine at the University of Toronto and Chair of the Toronto-based Canadian Heart Research Centre.
Conflict of Interest Disclosure

 

Mr. Allen Lefebvre
Allen Lefebvre has served in a number of management and volunteer leadership capacities in the last 25 years, primarily in the charitable and not-for-profit sectors. Now semi-retired, he was most recently engaged as the Project Coordinator for the Mâmawêyatitân Centre (formerly the North Central Shared Facility) in Regina — a major inner-city revitalization project.

Allen’s direct experience in the health care system came primarily as a result of his young son's cancer diagnosis in 1990 and the subsequent 15 years of treatment in the cancer care and critical care environments. Local and national volunteer involvement with the Canadian Cancer Society and the Candlelighters Canada Childhood Cancer Foundation led to his appointment as one of the founding members of the National Blood Safety Council in 1997. The organization advised the federal Minister of Health and conducted public forums on issues of blood safety in the wake of the Krever Commission. Allen served as a consumer representative and Vice-Chair of the Blood Safety Council until its dissolution in 2004. Allen has also been a public representative on the Drug Advisory Committee of Saskatchewan since 2010.
Conflict of Interest Disclosure

Dr. Kerry Mansell, BSP, PharmD
Dr. Mansell is an Associate Professor at the College of Pharmacy and Nutrition at the University of Saskatchewan. He teaches a variety of therapeutic topics, with a focus on diabetes. His research interests pertain to different aspects of diabetes management, as well as evaluating recent policy changes regarding pharmacist prescribing. Kerry also maintains a clinical practice in diabetes in the Saskatoon Health Region. He is currently a board member of the Canadian Pharmacists Association and Board Chair of the Association of Faculties of Pharmacy of Canada.
Conflict of Interest Disclosure

Dr. Yvonne Shevchuk, BSP, PharmD
Dr. Shevchuk is a Professor and Associate Dean Academic in the College of Pharmacy and Nutrition at the University of Saskatchewan, where her areas of teaching focus on infectious diseases, pharmacotherapeutics, and research methods/evidence-based pharmacotherapy and drug information. She is a long-time member of the Infectious Diseases Service at the Royal University Hospital and is involved in direct patient care. Yvonne has extensive committee experience, having served on both the Saskatchewan Formulary Committee and the Drug Quality Assessment Committee since 1991, and on the newly formed Drug Advisory Committee of Saskatchewan since January 2010. In addition, she is on the Board of the Saskatchewan Health Quality Council and the Advisory Board of RxFiles, and is Director of the Saskatchewan Drug Information Service.
Conflict of Interest Disclosure

Dr. Adil Virani, BSc Pharm, PharmD, FCSHP
Dr. Virani is a Director with Lower Mainland Pharmacy Services, which provides clinical and distribution services to hospitals within the Fraser Health Authority, Vancouver Coastal Health, and Providence Health Care, and some in the Provincial Health Services Authority. He is responsible for the Professional Practice portfolio, Residency and Student Education, Academic Detailing, and Pharmacy operations at some sites. He is an Associate Professor in the Faculty of Pharmaceutical Sciences at the University of British Columbia. He is also an editor of the Clinical Handbook of Psychotropic Drugs, now in its 21st edition, and editor of the Clinical Handbook of Psychotropic Drugs for Children and Adolescents, which is now in its 3rd edition. Adil is a member of the Education Working Group of the Therapeutics Initiative in British Columbia and the Human Drug Advisory Panel of the Patented Medicine Prices Review Board, and is a Fellow of the Canadian Society of Hospital Pharmacists.
Conflict of Interest Disclosure